← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Oncovir, Inc.
Washington, DC
$2,427,859
Total funding
3
Grants
Funding over time
peak $732.2K · FY2005–17$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$2,427,859 · 3
By mechanism
R44$1,689,340 · 1
R01$481,137 · 1
R43$257,382 · 1
Investigators at Oncovir, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
In-Situ Autovaccination against Solid Cancers with Intratumoral Hiltonol (Poly-ICLC): A phase II Adaptive Multicenter Clinical Study$732,170
R44 · FY2016 · CA
In-Situ Autovaccination against Solid Cancers with Intratumoral Hiltonol (Poly-ICLC): A phase II Adaptive Multicenter Clinical Study$732,170
R44 · FY2017 · CA
Poly-ICLC Prophylaxis Treatment of Ebola Virus Infection$481,137
R01 · FY2005 · AI
Hiltonol provides potent neuroprotection from ischemic brain injury in stroke.$257,382
R43 · FY2013 · NS
In-Situ Autovaccination against Solid Cancers with Intratumoral Hiltonol (Poly-ICLC): A phase II Adaptive Multicenter Clinical Study$225,000
R44 · FY2014 · CA